Nektar Therapeutics Aktie News

SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 5:15 p.m.

– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells – SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Ann...

Nektar Therapeutics (NASDAQ:NKTR ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jonathan Zalevsky - Chief, Research and Development Mary Tagliaferri - Chief Medical Officer Jennifer Ruddock - Chief Business Officer Conference Call Participants Jay Olson - Oppenheimer Charles Ferr...

SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in marketable securities at September 30, 2023, were $372.7 million as compared to $505.0 million at December 31, 2022.

SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period – – New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQI and POEM Endpoints – SAN FRANCISCO , Oct. 13, 2023  /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data...

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO , Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European A...